Bayer HealthCare Enters into Distribution Agreement to Expand Markets for the Medrad™ Intego™ PET Infusion System
LEVERKUSEN, Germany and TARRYTOWN, N.Y., March 5, 2013 /PRNewswire/ -- Bayer HealthCare is expanding its global distribution network for the Medrad™ Intego™ PET Infusion System through a new distribution agreement with Comecer, SPA, a world leader in protection technologies in nuclear medicine. Through this agreement, Bayer and Comecer are providing customers with an integrated nuclear medicine solution – combining the clinical administration capabilities of Intego with the Comecer's protection technologies for PET/CT centers around the world.
According to Doug Descalzi, Bayer HealthCare's Sr. Director of Molecular Imaging Devices, this distribution agreement capitalizes on the strength of both companies. "This arrangement creates an end-to-end solution for customers, from isotope production to radiopharmaceutical infusion. We're pleased to be working with Comecer to not only provide greater patient access to Intego but also to provide comprehensive product solutions to nuclear medicine suites around the world."
Intego is a worldwide market leader in PET/CT, and the only FDA-cleared system for administration of 18F-FDG and 18F-NaF. Intego infuses doses on-demand, providing clinicians with greater flexibility, enhanced workflow, added protection and more accurate, repeatable, patient-specific dosing. Now, through distribution with Comecer, clinicians in Europe and other markets will have easier access to this radiation dose reducing technology.
"Bayer has demonstrated incredible benefits to nuclear medicine facilities with the Intego PET Infusion System," said Emiliano Spagnolo, Director of Sales and Business Development for Comecer. "We are thrilled to take part in extending Intego to customers as part of our portfolio of solutions."
Since its launch in 2008, Bayer HealthCare has continued to enhance the Intego platform, adding software features, expanding compatibility and indications, and significantly reducing the size of the device. Bayer HealthCare will be showcasing the Intego PET Infusion System at the European Congress of Radiology (ECR) in Vienna, Austria, March 7-11, 2013.
About Comecer Group
Comecer Group is a world leader in protection technologies, hot cells manufacturing for nuclear medicine, isolation technology, and nuclear power plant protection/decommissioning. Comecer Group also produces screening software systems and equipment for special applications, designed for large industrial groups and research organizations. It works for hospitals, universities and pharmaceutical companies on tailored projects for the production of isolators for the treatment of toxic and hazardous substances. For more information visit http://www.comecer.com.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,300 employees (Dec 31, 2012) and is represented in more than 100 countries. More information at www.healthcare.bayer.com.
Our online press service is just a click away: www.press.bayerhealthcare.com
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
 PET = positron emission tomography; CT = computer tomography
SOURCE Bayer HealthCare
More by this Source
Bayer Receives Approval for Xofigo® (radium Ra 223 dichloride) Injection in Europe
Nov 15, 2013, 05:16 ET
500,000 People Call for Urgent Action to Prevent Atrial Fibrillation-Related Strokes
Oct 29, 2013, 09:12 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.